Excluding the ribosome and riboswitches, developing small molecules that selectively target RNA is a longstanding problem in chemical biology. A typical cellular RNA is difficult to target because it has little tertiary, but abundant secondary structure. We designed allele-selective compounds that target such an RNA, the toxic noncoding repeat expansion (r(CUG)exp) that causes myotonic dystrophy type 1 (DM1). We developed several strategies to generate allele-selective small molecules, including non-covalent binding, covalent binding, cleavage and on-site probe synthesis. Covalent binding and cleavage enabled target profiling in cells derived from individuals with DM1, showing precise recognition of r(CUG)exp. In the on-site probe synthesis approach, small molecules bound adjacent sites in r(CUG)exp and reacted to afford picomolar inhibitors via a proximity-based click reaction only in DM1-affected cells. We expanded this approach to image r(CUG)exp in its natural context.
You may also like
New study reveals ‘moonlighting’ function of part...
May 26, 2023Max Planck Institute for Brain Research
Competition between brain hemispheres during sleep
March 27, 2023Max Planck Institute for Brain Research
New Research Shows How Cultural Transmission Shapes...
March 27, 2023Max Planck Institute for Empirical Aesthetics
Modeling the turtle brain provides insights: Routing...
February 15, 2023Max Planck Institute for Brain Research
Amygdala Intercalated Cells: Gatekeepers and Conveyors...
January 19, 2023Max Planck Florida Institute for Neuroscience
Aversive bimodal associations differently impact...
January 19, 2023Max Planck Institute for Chemical Ecology